PXR can reduce blood glucose levels through the suppression of gluconeogenesis, making it a promising new therapeutic target for the prevention and treatment of obesity and type 2 diabetes. This evidence concerns the gene NR1I2 and obesity due to melanocortin 4 receptor deficiency.